REMAP-CAP Study: Rationale and Design

April 8, 2020

Here is the link that Berry Consultants and the international REMAP-CAP team describe the Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) study in a manuscript published in the Annals of the American Thoracic Society (AnnalsATS).

More Recent News

Blog: Time Trends in Clinical Trials (related to 2023 ASA Biopharm panel)

Blog by: Kert Viele On Thursday, I will be moderating a panel session (PS3B, 9/28/2023, 4:15-5:30 p.m.) at the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

ASA Biopharmaceutical Industry Statistics Workshop

Berry Consultants is proud to sponsor next week’s ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop on September 27-29 hosted in Rockville, MD. Multiple Berry Consultants team

Blog: If Bayesian inference doesn’t depend on the experimental design, then why does “Bayesian optimal design” exist?

Blog by: Kert Viele Bayesians draw conclusions based on posterior probabilities and utilities. Once an experiment is complete, Bayesian draw the same conclusions with the

New Public Webinar Series: Introduction to Adaptive Trial Designs using FACTS

Live Zoom webinar sessions open to the public on “Introduction to Adaptive Trial Designs using FACTS” will be held this October and November.

Made with ❤ by Austin Web Design